GGrantIndex
← Leaderboards

Holly C. Hagan

New York University

$12,864,700
Attributed
$12,864,700
Total exposure
12
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $5.1M · FY200525
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$34,070,277 · 13

By mechanism

P30$27,103,116 · 7
R01$6,595,657 · 5
R21$371,504 · 1

Top collaborators

Most similar at New York University

Same institution · by research overlap

Others in their field

Top investigators on “Epidemic

Research focus

EpidemicPreventionResearch PersonnelCommunitiesInnovationAids PreventionDrug UsageDrug UserCaringTheoriesResourcesPublic HealthStructureAreaBaseHiv InfectionsResearch MethodologyDisciplineCollaborationsTrendIncidenceEpidemiologyTrainingPharmaceutical Preparations

Grant awards (51)

Reinvigorating HIV Prevention and Care for People Who Use Drugs: Accelerating Progress and Sustaining Gains in the Midst of Societal Disruption$1,418,861
P30 · FY2025 · DA · contact PI
Reinvigorating HIV Prevention and Care for People Who Use Drugs: Accelerating Progress and Sustaining Gains in the Midst of Societal Disruption$544,116
P30 · FY2025 · DA · contact PI
Reinvigorating HIV Prevention and Care for People Who Use Drugs: Accelerating Progress and Sustaining Gains in the Midst of Societal Disruption$341,921
P30 · FY2025 · DA · contact PI
Reinvigorating HIV Prevention and Care for People Who Use Drugs: Accelerating Progress and Sustaining Gains in the Midst of Societal Disruption$135,758
P30 · FY2025 · DA · contact PI
Reinvigorating HIV Prevention and Care for People Who Use Drugs: Accelerating Progress and Sustaining Gains in the Midst of Societal Disruption$1,422,599
P30 · FY2024 · DA
Reinvigorating HIV Prevention and Care for People Who Use Drugs: Accelerating Progress and Sustaining Gains in the Midst of Societal Disruption$545,630
P30 · FY2024 · DA · contact PI
Reinvigorating HIV Prevention and Care for People Who Use Drugs: Accelerating Progress and Sustaining Gains in the Midst of Societal Disruption$341,921
P30 · FY2024 · DA · contact PI
Reinvigorating HIV Prevention and Care for People Who Use Drugs: Accelerating Progress and Sustaining Gains in the Midst of Societal Disruption$134,270
P30 · FY2024 · DA · contact PI
Reinvigorating HIV Prevention and Care for People Who Use Drugs: Accelerating Progress and Sustaining Gains in the Midst of Societal Disruption$1,506,082
P30 · FY2023 · DA
Reinvigorating HIV Prevention and Care for People Who Use Drugs: Accelerating Progress and Sustaining Gains in the Midst of Societal Disruption$546,911
P30 · FY2023 · DA · contact PI
Reinvigorating HIV Prevention and Care for People Who Use Drugs: Accelerating Progress and Sustaining Gains in the Midst of Societal Disruption$372,315
P30 · FY2023 · DA · contact PI
Reinvigorating HIV Prevention and Care for People Who Use Drugs: Accelerating Progress and Sustaining Gains in the Midst of Societal Disruption$147,954
P30 · FY2023 · DA · contact PI
Ending HIV/AIDS among People Who Use Drugs: Overcoming Challenges$1,475,726
P30 · FY2022 · DA · contact PI
A Nurse-Community Health Worker-Family Partnership Model to Increase COVID-19 Testing in Urban Underserved and Vulnerable Communities$1,174,281
P30 · FY2022 · DA
Ending HIV/AIDS among People Who Use Drugs: Overcoming Challenges$1,484,768
P30 · FY2021 · DA · contact PI
A Nurse-Community Health Worker-Family Partnership Model to Increase COVID-19 Testing in Urban Underserved and Vulnerable Communities$3,643,065
P30 · FY2020 · DA · contact PI
Ending HIV/AIDS among People Who Use Drugs: Overcoming Challenges$1,476,627
P30 · FY2020 · DA · contact PI
Ending HIV/AIDS among People Who Use Drugs: Overcoming Challenges$1,491,648
P30 · FY2019 · DA · contact PI
Ending HIV/AIDS among People Who Use Drugs: Overcoming Challenges$237,750
P30 · FY2019 · DA · contact PI
Ending HIV/AIDS among People Who Use Drugs: Overcoming Challenges$151,965
P30 · FY2019 · DA · contact PI
Ending HIV/AIDS among People Who Use Drugs: Overcoming Challenges$1,549,182
P30 · FY2018 · DA
Discovery to Implementation & Back: Research Translation for the HIV/SU Epidemic$1,354,410
P30 · FY2017 · DA
Transdisciplinary Research Methods Core$327,355
P30 · FY2017 · DA · contact PI
Discovery to Implementation & Back: Research Translation for the HIV/SU Epidemic$1,332,543
P30 · FY2016 · DA
Addressing Hepatitis C and Hepatocellular Carcinoma: Current and Future Epidemics$654,934
R01 · FY2016 · DA · contact PI
Transdisciplinary Research Methods Core$224,040
P30 · FY2016 · DA · contact PI
Discovery to Implementation & Back: Research Translation for the HIV/SU Epidemic$1,486,070
P30 · FY2015 · DA
Addressing Hepatitis C and Hepatocellular Carcinoma: Current and Future Epidemics$667,893
R01 · FY2015 · DA · contact PI
Addressing Hepatitis C and Hepatocellular Carcinoma: Current and Future Epidemics$584,331
R01 · FY2014 · DA · contact PI
Transdisciplinary Research Methods Core$220,931
P30 · FY2014 · DA · contact PI
Addressing Hepatitis C and Hepatocellular Carcinoma: Current and Future Epidemics$634,335
R01 · FY2013 · DA · contact PI
Transdisciplinary Research Methods Core$247,083
P30 · FY2013 · DA · contact PI
INTERDISCIPLINARY RESEARCH METHODS CORE$349,936
P30 · FY2012 · DA · contact PI
INTERDISCIPLINARY RESEARCH METHODS CORE$312,657
P30 · FY2011 · DA · contact PI
INTERDISCIPLINARY RESEARCH METHODS CORE$376,273
P30 · FY2010 · DA · contact PI
INTERDISCIPLINARY RESEARCH METHODS CORE$389,377
P30 · FY2009 · DA · contact PI
INTERDISCIPLINARY RESEARCH METHODS CORE$232,256
P30 · FY2008 · DA · contact PI
Reducing HIV Transmission by Promoting Sexual Health among Drug Users$108,750
R21 · FY2008 · DA · contact PI
Reducing HIV Transmission by Promoting Sexual Health among Drug Users$262,754
R21 · FY2007 · DA · contact PI
Research Methods$106,835
P30 · FY2007 · DA · contact PI
Synthesis: HCV Epidemiology and Prevention in Drug Users$412,934
R01 · FY2006 · DA · contact PI
Etiology and Prevention of Blood borne Viruses in IDUs$331,181
R01 · FY2006 · DA · contact PI
Etiology and Prevention of Blood borne Viruses in IDUs$474,023
R01 · FY2005 · DA
Synthesis: HCV Epidemiology and Prevention in Drug Users$413,389
R01 · FY2005 · DA
Etiology and Prevention of Blood borne Viruses in IDUs$532,936
R01 · FY2004 · DA
Synthesis: HCV Epidemiology and Prevention in Drug Users$445,145
R01 · FY2004 · DA
Etiology and Prevention of Blood borne Viruses in IDUs$558,367
R01 · FY2003 · DA
Etiology and Prevention of Blood borne Viruses in IDUs$42,221
R01 · FY2002 · DA
Etiology and Prevention of Blood borne Viruses in IDUs$327,056
R01 · FY2001 · DA
HEPATITIS C IN IDUS--EPIDEMIOLOGY AND PREVENTION$473,068
R01 · FY2000 · DA
RAVEN STUDY--ADVANCING HIV PREVENTION FOR IDUS$43,844
R01 · FY2000 · DA